Hanmi Pharmaceutical
14 Wiryeseong-daero, Songpa-gu, Seoul, 05545, South Korea
Overview
Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Biotechnology
- Health Care
Investment portfolio
- MEDiC
Led · Equity · Oct 2024
MEDiC Life Sciences develops a next-generation functional genomics platform (MCAT™) that measures millions of gene-to-drug interactions and identifies SLS™ biomarkers to improve cancer drug response and expand market potential. The company uses 3D tumor models to increase the accuracy and translatability of target and biomarker discovery for solid tumors. MEDiC partners with pharmaceutical companies including Bristol Myers Squibb and Hanmi to deliver biomarkers and targets to enhance oncology pipelines and pursue clinical validation collaborations. The new $5M strategic investment from LG and Hanmi will be used to accelerate adoption of its technology, bolster business development, and advance early drug discovery efforts. MEDiC previously raised an $8M seed led by a group including Illumina Accelerator, Top Harvest Capital, Primer Sazze, Big Basin Capital, First In Ventures, Valuence Ventures, Gradient, and Wing Venture Capital. Founded in 2020 and based in Mountain View, California, the company is co‑founded by CEO Kyuho Han, Ph.D., and CTO Hong‑Pyo Lee.
- Allegro Ophthalmics
Led · Equity · Jan 2015
Allegro Ophthalmics is a biotechnology company focused on developing novel therapies for vitreoretinal diseases. Its lead investigational drug, Luminate, is a first-in-class integrin peptide therapy that targets integrin receptors and employs two mechanisms of action (vitreolysis and anti-angiogenesis). Luminate has met endpoints in two Phase 2 monotherapy studies for diabetic macular edema (DME) and vitreomacular traction (VMT), and topline results from a Phase 2, Stage 2 DME trial evaluating Luminate in combination with anti-VEGFs are expected soon. The drug has been shown in clinical studies to regress and inhibit new blood-vessel formation and reduce vascular leakage, and it is not approved by the FDA for commercial sale in the U.S. Allegro holds commercial rights to Luminate in all territories outside Japan, Korea and China. The company says recent financing positions it to complete multiple Phase 2 trials and prepare for Phase 3 studies. Allegro Ophthalmics develops Luminate (ALG-1001), a first-in-class Integrin Peptide Therapy currently in multiple Phase 2 studies in the U.S. for vitreo-retinal conditions including diabetic macular edema, wet age-related macular degeneration, and vitreomacular traction. Luminate acts on integrin receptors with dual mechanisms (anti-angiogenesis and vitreolysis) to regress neovascularization and reduce vascular leakage, and has shown promise in clinical studies to date. Allegro positions Luminate to potentially reduce the burden of intravitreal injections and offer an alternative treatment option for patients at risk of vision loss. The company retains commercial rights to Luminate in all territories outside Japan, Korea and China. Allegro highlights more than 100 years of combined team experience in ophthalmic drug discovery, development and manufacturing and is focused on advancing its global clinical program. The announced strategic partnership and investment from Hanmi Pharmaceutical is intended to provide capital to accelerate development and commercialization efforts in Asia and globally.